Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Exanthema × ruxolitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 16 Leukemia, Myeloid, Acute 16 Primary Myelofibrosis 12 Polycythemia Vera 11 Leukemia 9 Myeloproliferative Disorders 8 Myelodysplastic Syndromes 8 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7 Recurrence 6 Hematologic Neoplasms 6 Breast Neoplasms 6 Myelodysplastic-Myeloproliferative Diseases 5 Leukemia, Myelomonocytic, Chronic 5 Hodgkin Disease 5 Thrombocythemia, Essential 4 Leukemia, Myeloid, Chronic-Phase 4 Leukemia, Lymphocytic, Chronic, B-Cell 4 Graft vs Host Disease 4 Triple Negative Breast Neoplasms 3 Prostatic Neoplasms 3 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3 Multiple Myeloma 3 Lymphoma, T-Cell, Cutaneous 3 Lymphoma, T-Cell 3 Lymphoma, Non-Hodgkin 3 Lymphoma 3 Leukemia, Prolymphocytic, T-Cell 3 Squamous Cell Carcinoma of Head and Neck 2 Pancreatic Neoplasms 2 Neoplasm Metastasis 2

Interventions

Fulvestrant 2 ruxolitinib 1 dexpanthenol 1 ceterizine hydrochloride 1 capivasertib 1 benralizumab 1 Provitamins 1 Prednisone 1 Loperamide 1 Interviews as Topic 1 HIV Testing 1 Gels 1 Fibroblast Growth Factor 7 1 Doxycycline 1 Dapsone 1 Cetuximab 1 Anti-Bacterial Agents 1 Alpelisib 1 Acitretin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06399029 2025-11-19

TRUX-LST

University of Zurich

Phase 2 Recruiting

Exanthema

Data powered by HemOnc (CC BY 4.0) Colophon ⚡